James DArecca - 16 May 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role: EVP, Chief Financial Officer
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca
Issuer symbol: HAE
Transactions as of: 16 May 2022
Net transactions value: $0
Form type: 4
Filing time: 18 May 2022, 16:34:44 UTC
Previous filing: 04 May 2022
Next filing: 04 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HAE	Common Stock	Award		+4,774	+81%		10,676	16 May 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HAE	Non-qualified Stock Option (Right to Buy)	Award	$0	+11,163		$0.000000	11,163	16 May 2022	Common Stock	11,163	$57.60	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2	Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3	This number includes unvested RSUs previously reported.
F4	Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.